Sino Biopharmaceutical Ltd

01177

Company Profile

  • Business description

    Listed on the Hong Kong Stock Exchange in 2000, Sino Biopharmaceutical is one of the largest Chinese drugmakers. It started with generic drug manufacturing. Since 2018, Sino Biopharm has been actively pivoting into an innovative drugmaker after the Chinese government launched its volume-based procurement policy for the healthcare industry. As of 2024, 41.8% of the firm's total revenue comes from its innovative product category, which includes innovative drugs and biosimilar drugs. Sino Biopharm’s biggest revenue segment is oncology medicines, accounting for 37.2% of total revenue, followed by hepatitis, surgery/analgesia, respiratory, and cardio-cerebral vascular therapeutic areas.

  • Contact

    1 Harbour Road
    Unit 09, 41st Floor, Office Tower, Room 4109
    Convention Plaza
    Wanchai
    Hong Kong
    HKG

    T: +852 28029886

    https://www.sinobiopharm.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    23,056

Stocks News & Analysis

stocks

3 Warren Buffett stocks to avoid today

These are the most overvalued stocks in Berkshire Hathaway’s portfolio.
stocks

Should you invest in small caps?

With small capitalisation stocks gaining momentum, there are important considerations to determine whether they are right for your portfolio. 
stocks

Strong second half anticipated for ASX mining play

A more focused business model should benefit the company.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,079.2017.700.20%
CAC 407,870.6875.260.97%
DAX 4023,739.47204.640.87%
Dow JONES (US)46,247.29299.970.65%
FTSE 1009,284.8370.850.77%
HKSE26,128.20356.48-1.35%
NASDAQ22,484.0799.370.44%
Nikkei 22545,354.99399.94-0.87%
NZX 50 Index13,111.7342.06-0.32%
S&P 5006,643.7038.980.59%
S&P/ASX 2008,787.7013.200.15%
SSE Composite Index3,828.1125.20-0.65%

Market Movers